Terufumi Kato

机构：Kanagawa Prefectural Hospital Organization, Tokyo Metropolitan Komagome Hospital, Kanagawa Cancer Center · ORCID：0000-0002-5853-1424

发表论文 527 篇 · 总被引 31196 次 · h-index 59

代表论文

• Clinical Characteristics and Surgical Outcomes of Patients Receiving Perioperative Pembrolizumab in KEYNOTE-671 (2025 · The Annals of Thoracic Surgery · 被引 8)
• LBA67 Perioperative pembrolizumab in early-stage non-small- cell lung cancer (NSCLC): 5-year follow-up from KEYNOTE- 671 (2025 · Annals of Oncology · 被引 7)
• KEYNOTE ‐ A17 : First‐Line Pembrolizumab Plus Cisplatin–Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma (2025 · Cancer Science · 被引 6)
• Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 study (2025 · The Lancet Oncology · 被引 5)
• Safety and effectiveness of tepotinib in patients with unresectable, advanced or recurrent non-small cell lung cancer with METex14 skipping alterations: post-marketing surveillance in Japan (2025 · Japanese Journal of Clinical Oncology · 被引 3)
• Longer follow-up for survival and safety from the EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel in patients (pts) with metastatic non-small cell lung cancer (mNSCLC). (2025 · Journal of Clinical Oncology · 被引 2)